CAM
NGNE icon

Cormorant Asset Management’s Neurogene NGNE Stock Holding History

Cormorant Asset Management’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-107,344
Closed -$4.5M – 51
2024
Q3 		$4.5M Hold
107,344
– – 0.24% 40
2024
Q2 		$3.91M Sell
107,344
-431,370
-80% -$15.2M 0.23% 44
2024
Q1 		$27.4M Sell
538,714
-207,466
-28% -$6.93M 1.2% 28
2023
Q4 		$14.5M Buy
+746,180
New +$10.7M 0.69% 33
2017
Q1 		– Sell
-7,592
Closed -$2.51M – 77
2016
Q4 		$2.51M Hold
7,592
– – 0.34% 57
2016
Q3 		$2.03M Hold
7,592
– – 0.22% 66
2016
Q2 		$1M Buy
7,592
+92
+1% +$14.6K 0.14% 67
2016
Q1 		$1.32M Hold
7,500
– – 0.2% 65
2015
Q4 		$1.87M Hold
7,500
– – 0.22% 62
2015
Q3 		$2.11M Sell
7,500
-6,495
-46% -$1.5M 0.34% 58
2015
Q2 		$1.94M Hold
13,995
– – 0.26% 63
2015
Q1 		$2.3M Sell
13,995
-1,005
-7% -$204K 0.36% 56
2014
Q4 		$2.25M Hold
15,000
– – 0.35% 53
2014
Q3 		$2M Hold
15,000
– – 0.41% 50
2014
Q2 		$2.83M Buy
15,000
+2,656
+22% +$512K 0.75% 45
2014
Q1 		$3.14M Buy
+12,344
New +$3.17M 0.72% 39

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Cormorant Asset Management's NGNE Position: Q4 2024 in Review

Cormorant Asset Management sold out of Neurogene (NGNE) in Q4 2024, closing a stake of 107,344 shares — an estimated $4.5M sold.

Cormorant Asset Management first reported a position in NGNE in Q1 2014 and held it in 16 quarters. The position peaked at $27.4M in Q1 2024. 88 funds tracked by Wall St. Rank hold NGNE as of Q4 2024.

  • Cormorant Asset Management reported no remaining Neurogene position as of Q4 2024 after selling out during the quarter.
  • Cormorant Asset Management sold 107,344 Neurogene shares in Q4 2024, an estimated $4.5M.
  • Cormorant Asset Management first reported a position in Neurogene in Q1 2014 and held it in 16 quarters.
  • Cormorant Asset Management's Neurogene position peaked at $27.4M in Q1 2024.
  • 88 funds tracked by Wall St. Rank held Neurogene as of Q4 2024.

Based on Cormorant Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.